A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
for Thromboangiitis Obliterans (Buerger's Disease)
1 location in Overland Park
Sponsor: Antidote Therapeutics, Inc
Sex: All·Age: 23 - 59·Accepts healthy volunteers
Code: NCT07215923·Phase 1·Recruiting·Listed Oct 2025